Aequus Pharmaceuticals (AQS) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free AQS Stock Alerts C$0.02 -0.01 (-20.00%) (As of 05/17/2024 02:34 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsHeadlinesInsider TradesStock AnalysisChartEarningsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 2, 2024 | finance.yahoo.comAequus Pharmaceuticals Full Year 2023 Earnings: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)April 20, 2024 | seekingalpha.comAQS:CA Aequus Pharmaceuticals Inc.February 23, 2024 | theglobeandmail.comZoomd Technologies: Top 10 Undervalued Growth Stocks on TSX-V (ZOMD)February 18, 2024 | theglobeandmail.comAequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)December 12, 2023 | morningstar.comAequus Pharmaceuticals Inc AQSNovember 30, 2023 | msn.comAequus Pharmaceuticals reports Q3 resultsOctober 18, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc up on Thursday (AQS)October 7, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc flat on Thursday (AQS)October 5, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc flat on Tuesday (AQS)September 29, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc flat on Friday (AQS)September 29, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc flat on Wednesday (AQS)August 30, 2023 | finanznachrichten.deAequus Pharmaceuticals: Aequus Reports Second Quarter 2023 Financial Highlights and General UpdateAugust 29, 2023 | markets.businessinsider.comAequus Reports Second Quarter 2023 Financial Highlights and General UpdateAugust 25, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc up on Wednesday (AQS)August 24, 2023 | finance.yahoo.comAequus Announces Zimed PF Now Available in CanadaAugust 22, 2023 | finance.yahoo.comAequus Announces Zimed PF Website LaunchAugust 18, 2023 | finance.yahoo.comAequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in CanadaJuly 6, 2023 | benzinga.comAequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)June 7, 2023 | ca.finance.yahoo.comAQS.V - Aequus Pharmaceuticals Inc.May 31, 2023 | finanznachrichten.deAequus Pharmaceuticals: Aequus Provides General Update and First Quarter 2023 Financial HighlightsMay 31, 2023 | finance.yahoo.comAequus Provides General Update and First Quarter 2023 Financial HighlightsMay 2, 2023 | finance.yahoo.comAequus Provides General Update and Fiscal 2022 Financial ResultsApril 19, 2023 | finance.yahoo.comAequus Grants Stock OptionsApril 5, 2023 | finance.yahoo.comAequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board UpdateMarch 26, 2023 | finance.yahoo.comAequus Pharmaceuticals Inc. (AQS.V)December 20, 2022 | finance.yahoo.comAequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)December 3, 2022 | yahoo.comAequus Pharmaceuticals Third Quarter 2022 Earnings: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)November 30, 2022 | finanznachrichten.deAequus Pharmaceuticals: Aequus Reports Third Quarter 2022 Financial HighlightsNovember 30, 2022 | finance.yahoo.comAequus Reports Third Quarter 2022 Financial HighlightsNovember 29, 2022 | finance.yahoo.comAequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free)October 9, 2022 | reuters.comAequus Pharmaceuticals IncAugust 30, 2022 | seekingalpha.comAequus Pharmaceuticals reports Q2 resultsAugust 29, 2022 | finance.yahoo.comAequus Reports Second Quarter 2022 Financial Highlights and General UpdateJuly 13, 2022 | finance.yahoo.comIIROC Trading Resumption - AQSJuly 13, 2022 | finance.yahoo.comAequus Resumes Trading on TSX Venture ExchangeJuly 1, 2022 | financialpost.comAequus Provides General Update and Reports Record 2021 Financial ResultsMay 7, 2022 | stockhouse.comAequus Provides Update on Delay in Filing Annual Financial StatementsMay 2, 2022 | finance.yahoo.comIIROC Trading Halt - AQS.WTMay 2, 2022 | finance.yahoo.comIIROC Trading Halt - AQS.DBMay 2, 2022 | stockhouse.comAequus Announces Short Term LoanApril 22, 2022 | benzinga.comAequus Announces Director ResignationJanuary 11, 2022 | finance.yahoo.comSandoz and Aequus Agree to 1-Year Extension on Vistitan in CanadaJanuary 6, 2022 | finance.yahoo.comAequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma MedicationNovember 5, 2021 | ca.finance.yahoo.comIs Aequus Pharmaceuticals (CVE:AQS) Weighed On By Its Debt Load?November 3, 2021 | apnews.comAequus Reports Third Quarter 2021 Financial HighlightsAugust 30, 2021 | stockhouse.comAequus Reports Second Quarter 2021 Financial HighlightsAugust 25, 2021 | finance.yahoo.comAequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology ExpertiseAugust 17, 2021 | prnewswire.comAequus and reVision to Collaborate on Stargardt Disease Program Get Aequus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQS and its competitors with MarketBeat's FREE daily newsletter. Email Address What President Biden's new law means for investors (Ad)What's Got Musk, Bezos, and Gates So Excited? Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it. This expert just went public with all the details, including which stocks to jump on immediately. AQS Media Mentions By Week AQS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AQS News Sentiment▼0.000.42▲Average Medical News Sentiment AQS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AQS Articles This Week▼00▲AQS Articles Average Week Get Aequus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ENTG News Today DN News Today VM News Today AH News Today CTX News Today VPH News Today WLLW News Today MPH News Today NDVA News Today HEM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:AQS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDoes this make you sick?Allegiance GoldThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aequus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
